The FDA’s emergency use authorisation for plasma for Covid-19 looks questionable. If this presages an early vaccine nod, we should be very afraid.
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
Revelations of data manipulation might not be fatal, but they will hurt the chief exec’s attempted rebranding of Novartis as a more ethical pharma company.